Ann: Two PTX abstracts accepted at prestigious ISCT conference, page-30

I would have thought the reason to sell it hard is because we have new pre-clinical data is available to unveil... well that's how I read it. If we do but the company doesn't release it in an ASX ann to the broader market, then I will be equally p!$$sed if the word "new" pertains to nothing "new". However, with the way bidders keep stepping up to the 8.1c line, suggests that there has been a lot of soaking taking place.



I would dare say that profits are being skimmed from another sector that are being used to quietly build positions in the laggards of the bio sector. One only has to look at what a bit of early anticipation for pre-clinical data can do for a beaten down stock - aka a Hopper sibling that this year went up 5-fold and still holding at half that accretion.